Irifrin eye drops 2.5% 5 ml. vial cap.№1

Description

Irifrin Storage

active substance: phenylephrine;

1 ml of the drug contains phenylephrine hydrochloride 25 mg;

Excipients: benzalkonium chloride, disodium edetate, hypromellose, sodium metabisulfite (E 223), sodium citrate, citric acid anhydrous, water for injections.

Irifrin Dosage form

Eye drops.

main physical and chemical properties: clear, colorless or slightly yellowish solution.

Pharmacotherapeutic group. Means used in ophthalmology. Mydriatic and cycloplegic drugs. ATC code S01F B01.

Irifrin Pharmacological properties

Pharmacodynamics

The drug has a pronounced stimulating effect on postsynaptic alpha-adrenoreceptors, with no effect on beta-adrenoceptors of the heart. The drug has a vasoconstrictive effect similar to that of norepinephrine, but it has almost no chronotropic and inotropic effect on the heart. The vasopressor effect of the drug is less pronounced than that of norepinephrine, but much longer. When used in normal doses does not show a significant stimulating effect on the central nervous system. After instillation, phenylephrine shortens the dilator of the pupil, thereby causing it to dilate, and the smooth muscles of the conjunctival arterioles. There is no effect on the ciliary muscle, so mydriasis occurs without cycloplegia.

Pharmacokinetics

Phenylephrine easily penetrates the eye tissue, pupil dilation occurs within 10-60 minutes after a single instillation. Mydriasis persists for 4-6 hours. Due to the significant reduction of the pupil dilator in 30-45 minutes after instillation in the moisture of the anterior chamber of the eye can be found particles of pigment from the pigment leaf of the iris. This phenomenon must be distinguished from the manifestations of anterior uveitis or from the presence of formed elements of blood in the moisture of the anterior chamber.

Clinical characteristics

Indication

· Iridocyclitis, anterior uveitis (for the treatment and prevention of posterior synechiae and reduction of exudation from the iris).

· Diagnostic dilation of the pupil during ophthalmoscopy and other diagnostic procedures needed to determine the condition of the posterior segment of the eye.

· Conducting a provocation test in patients with a narrow anterior chamber angle profile and suspected angle-closure glaucoma.

· Differential diagnosis of the type of eyeball injection.

· Pupil dilation during laser interventions on the fundus and vitreoretinal surgery.

· Red eye syndrome (to reduce redness and irritation of the eyelids).

· Complex therapy of accommodation spasm in school-age children.

· Treatment and prevention of asthenopia.

Contraindication

─ Hypersensitivity to any component of the drug.

─ Narrow-angle or closed-angle glaucoma.

─ Significant disorders of the cardiovascular system (heart disease, hypertension, aneurysm, tachycardia), especially in elderly patients.

─ Insulin-dependent diabetes mellitus.

─ Thyrotoxicosis.

─ Hyperthyroidism.

─ Concomitant use with monoamine oxidase inhibitors (MAOIs) and use within 2 weeks after stopping treatment with MAOIs.

─ Additional dilation of the pupil during surgery in patients with impaired integrity of the eyeball or with impaired tear function.

─ Concomitant use with tricyclic antidepressants, antihypertensive drugs (including beta-blockers).

─ Congenital deficiency of glucose-6-phosphate hydrogenase.

─ Hepatic porphyria.

─ Contraindicated in low birth weight infants.

─ Contraindicated in newborns and infants with cardiovascular or cerebrovascular disorders.

─ Contraindicated in elderly patients with severe arteriosclerotic, cardiovascular or cerebrovascular diseases.